AstraZeneca PLC (AZN)vsSpero Therapeutics Inc (SPRO)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
SPRO
Spero Therapeutics Inc
$2.51
-0.79%
HEALTHCARE · Cap: $154.60M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 87830% more annual revenue ($58.74B vs $66.80M). AZN leads profitability with a 17.4% profit margin vs 12.8%. SPRO trades at a lower P/E of 17.8x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
SPRO
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+51.9%
Fair Value
$4.95
Current Price
$2.51
$2.44 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Strong operational efficiency at 76.0%
Revenue surging 174.5% year-over-year
Earnings expanding 75.3% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : SPRO
The strongest argument for SPRO centers on Operating Margin, Revenue Growth, EPS Growth. Revenue growth of 174.5% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : SPRO
The primary concerns for SPRO are Market Cap, Free Cash Flow.
Key Dynamics to Monitor
AZN profiles as a value stock while SPRO is a growth play — different risk/reward profiles.
SPRO carries more volatility with a beta of 1.45 — expect wider price swings.
SPRO is growing revenue faster at 174.5% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 63/100), backed by strong 17.4% margins. SPRO offers better value entry with a 51.9% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Spero Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multidrug resistant (MDR) bacterial infections and rare diseases in the United States. The company is headquartered in Cambridge, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?